K.H. Lu

PARP inhibitors: Synthetic lethality in the clinic

Triple-negative breast cancer molecular subtyping and treatment progress

The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications

Hepatocellular carcinoma

BRCAness revisited

PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions

A fluorescent probe capable of detecting H2S at submicromolar concentrations in cells

Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative.

Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future

Macrophages in immunoregulation and therapeutics

Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease

High-performance liquid chromatographic methods for the determination of topoisomerase II inhibitors

Natural products to drugs: natural product-derived compounds in clinical trials

EMT: 2016

Analysis of anticancer drugs: A review

Biological and Therapeutic Impact of Intratumor Heterogeneity in Cancer Evolution

The PI3K Pathway in Human Disease

Using sulfuramidimidoyl fluorides that undergo sulfur(vi) fluoride exchange for inverse drug discovery

Tumour heterogeneity and resistance to cancer therapies

The role of carboplatin in the neoadjuvant chemotherapy treatment of triple negative breast cancer

Phase I study of amonafide dosing based on acetylator phenotype.

Safety and Efficacy of Using a Single Agent or a Phase II Agent Before Instituting Standard Combination Chemotherapy in Previously Untreated Metastatic Breast Cancer Patients: Report of a Randomized Study—Cancer and Leukemia Group B 8642

Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.

Drug Level Monitoring: Cytostatics

Design Strategies for Water-Soluble Small Molecular Chromogenic and Fluorogenic Probes

Identification and use of biomarkers in treatment strategies for triple‐negative breast cancer subtypes

Pharmacokinetics and metabolism of the antitumor drug amonafide (NSC-308847) in humans.

Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer

Phase I clinical trial and pharmacokinetic evaluation of 4?-0-tetrahydropyranyladriamycin (THP-adriamycin)

High-Performance Liquid Chromatography (HPLC) of the New Antineoplastic 9,10-Anthracenedicarboxaldehyde Bis[(4,5-Dihydro-1 H-Imidazole-2-yl)hydrazone] dihydrochloride (CL 216,942; Bisantrene)